MicroRNA and metabolomics signatures for adrenomyeloneuropathy disease severity

MicroRNA and metabolomics signatures for adrenomyeloneuropathy disease severity

Abstract Adrenomyeloneuropathy (AMN), the slow progressive phenotype of adrenoleukodystrophy (ALD), has no clinical plasma biomarker for disease progression. This feasibility study aimed to determine whether metabolomics and micro‐RNA in blood plasma provide a potential source of biomarkers for AMN...

Full description

Bibliographic Details
Main Authors: Bela Rui Turk, Laila Marie Poisson, Christina Linnea Nemeth, Jordan Goodman, Ann B. Moser, Richard Owen Jones, Ali Fatemi, Jaspreet Singh
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:JIMD Reports
Subjects:
adrenoleukodystrophy
adrenomyeloneuropathy
biomarker
leukodystrophy
metabolomics
micro‐RNA
Online Access:https://doi.org/10.1002/jmd2.12323

Internet

https://doi.org/10.1002/jmd2.12323

Similar Items